Fluralaner

Summary of opinion: Bravecto, 05/12/2023 Positive

Retrieved on: 
Saturday, December 30, 2023
Marketing, Fluralaner, European Commission, Cat, Civil service commission, Solution, Dog, UPD, European Medicines Agency, CVMP, Intention, Tablet, Committee, SPC

On 5-7 December 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Bravecto.

Key Points: 
  • On 5-7 December 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Bravecto.
  • The marketing authorisation holder for this veterinary medicinal product is Intervet International B.V.
    Bravecto is currently authorised as chewable tablets and spot-on solutions for dogs and cats.
  • The variation concerns the addition of a new pharmaceutical form, 150 mg/ml powder and solvent for suspension for injection, for dogs.
  • 1Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Summary of opinion: Bravecto, 05/12/2023 Positive

Retrieved on: 
Monday, December 18, 2023
Cat, SPC, European Medicines Agency, European Commission, UPD, Fluralaner, Tablet, Civil service commission, Marketing, Solution, Committee, Intention, CVMP, Dog

On 5-7 December 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Bravecto.

Key Points: 
  • On 5-7 December 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Bravecto.
  • The marketing authorisation holder for this veterinary medicinal product is Intervet International B.V.
    Bravecto is currently authorised as chewable tablets and spot-on solutions for dogs and cats.
  • The variation concerns the addition of a new pharmaceutical form, 150 mg/ml powder and solvent for suspension for injection, for dogs.
  • 1Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Companion Animal Health Market Report 2022: Rising Pet Ownership Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Veterinary, Health, Animal, Infection, American Pet Products Association, Merck, Statistics, Tick, Tablet, Dog, Cat, Vaccine, Growth, APPA, Bayer, Prevalence, Companion, Parasitism, Acquisition, PETS, Policy, Fluralaner, Science, Pet, Diarrhea

With the rising companion animal ownership population, owners are concerned about companion animal health and nutrition, and thereby seeking various veterinary services.

Key Points: 
  • With the rising companion animal ownership population, owners are concerned about companion animal health and nutrition, and thereby seeking various veterinary services.
  • Similarly, acquisitions by major players are increasing the demand for companion animal health market across the globe.
  • A major strategy that is implemented by companies in the companion animal health market is collaboration with one another, a crucial reason for the development of companion animal health market across the globe.
  • One of the key factors which supports the growth of companion animal health market is the wide availability of pet care products in North America.

National Advertising Review Board Recommends Merck Discontinue "Best in Show" Commercial for Bravecto Flea and Tick Preventative for Dogs

Retrieved on: 
Thursday, May 5, 2022
Privacy, Schering-Plough, Best in Show, Council, Merck, Uniloc USA, Inc. v. Microsoft Corp., CARU, Public sector, Fluralaner, Industry, Compliance, Advertising, Better Business Bureau, Tick, View, Afoxolaner, NAD, Multimedia, Pharmaceutical industry

The advertising at issue had been challenged before the National Advertising Division (NAD) by Boehringer Ingelheim Animal Health USA Inc., maker of NexGard.

Key Points: 
  • The advertising at issue had been challenged before the National Advertising Division (NAD) by Boehringer Ingelheim Animal Health USA Inc., maker of NexGard.
  • 7029 ), Merck appealed NAD's recommendation that it discontinue its 30-second "Best in Show" television commercial.
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.
  • About the National Advertising Review Board (NARB):The National Advertising Review Board(NARB)is the appellate body for BBB National Programs' advertising self-regulatory programs.

National Advertising Division Recommends Merck Discontinue "Best in Show" Commercial for Bravecto Flea and Tick Preventative for Dogs; Merck to Appeal

Retrieved on: 
Thursday, February 3, 2022
Association of National Advertisers, Better Business Bureau, Best in Show, Uniloc USA, Inc. v. Microsoft Corp., Television, NAD, Schering-Plough, Dog, Council, Advertising, Privacy, Afoxolaner, Merck, CARU, Fluralaner, Multimedia, Pharmaceutical industry

better than NexGard at preventing flea and tick infestations when both products are used as directed.

Key Points: 
  • better than NexGard at preventing flea and tick infestations when both products are used as directed.
  • NexGard is ineffective, even when dosed according to the package directions, at preventing flea infestations after week five.
  • Such appeals of NAD decisions are made to the BBB National Programs' National Advertising Review Board (NARB), the appellate-level truth-in-advertising body of BBB National Programs.
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.

Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews

Retrieved on: 
Thursday, July 9, 2020
Science, Veterinary, Research, Pharmaceutical, Pets, Health, FDA, Consumer, Companies, Chemical compounds, Pharmaceutical companies, Bayer AG, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Merck, Fluralaner

View the full release here: https://www.businesswire.com/news/home/20200709005926/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200709005926/en/
    Merck Animal Health Receives U.S. FDA Approval of BRAVECTO (fluralaner) Monthly Chews (Photo: Business Wire)
    BRAVECTO 1-MONTH is an important addition to the companys parasiticide portfolio, which are extended duration flea and tick protection products that offer broad-spectrum, comprehensive parasite protection for dogs.
  • Parasites pose serious animal and human health risks as fleas and ticks can transmit disease, said Christine Royal, DVM, executive director, U.S. Companion Animal and Equine Professional Services, Merck Animal Health.
  • Sure Petcare, along with HomeAgain, is a Companion Animal portfolio of digital products within Merck Animal Health.
  • Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.